Demetrix uses genetically engineered yeast fermentation to produce a range of cannabinoids that are rare or present in very small amounts in the cannabis plant. The company launched with an $11 million seed round led by Horizons Ventures to commercialize research from Jay Keasling’s lab. It has since raised another $50 million from Horizons Ventures and Tuatara Capital to significantly expand production and to pursue initial efficacy tests on rare cannabinoid strains as potential treatments. Demetrix plans to target pharmaceuticals, consumer health, wellness and beauty applications, and supplements. The company has been working closely with the FDA and equivalent regulators and has not yet supplied its cannabinoids while it scales manufacturing and completes regulatory work. Leadership says the firm is aiming to bring products into consumer and supplement channels within roughly three years.

Total raised

$50M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2019